If data is made open, it will do the exact opposite of what you're saying. Instead of enabling big pharma to hide its mistakes, it will allow independent groups to show where problems exist.
Of course, independent studies are already conducted, but no matter how well controlled they are, when cohort sizes are only tens to hundreds of people, there's no way you can properly assess a drug's safety.